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With Newly Diagnosed Cardiomyopathy
A Decade-Long Single-Center ExperienceMadhurmeet Singh, DO, Norman C. Wang, MD, MS, Sandeep Jain, MD, Andrew H. Voigt, MD, Samir Saba, MD,
Evan C. Adelstein, MDABSTRACTFro
su
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pa
MaBACKGROUND The wearable cardioverter-deﬁbrillator (WCD) has emerged as a means of protecting patients with
newly diagnosed nonischemic cardiomyopathy (NICM) or ischemic cardiomyopathy (ICM) against sudden cardiac death
while awaiting re-evaluation of cardiac function.
OBJECTIVES This study sought to characterize the risk of appropriate WCD therapy in newly diagnosed NICM and ICM
patients according to cardiomyopathy etiology in an independent study.
METHODS Medical records of all patients prescribed a WCD between June 2004 and May 2015 at our institution
(n ¼ 639) were analyzed, focusing on 254 patients with newly diagnosed NICM and 271 patients with newly
diagnosed ICM. Patients with a prior implantable cardioverter-deﬁbrillator or sustained ventricular arrhythmias were
excluded (n ¼ 114). The primary endpoint was appropriate WCD therapy.
RESULTS Median WCD wear time was 61 days (interquartile range [IQR]: 25 to 102 days) per patient and 22 h/day
(IQR: 17 to 23 h/day). During 56.7 patient-years, 0 NICM patients received an appropriate WCD shock, whereas 3 (1.2%)
received an inappropriate shock. During 46.7 patient-years, 6 (2.2%) ICM patients received an appropriate shock; 5
survived the episode, and 4 survived to hospital discharge. All 6 patients with an appropriate shock were male with QRS
duration >120 ms. Two (0.7%) ICM patients received an inappropriate shock.
CONCLUSIONS In this independent, retrospective study, the risk of appropriate WCD therapies in patients with
newly diagnosed NICM was minimal. Routine use of the WCD in this population should be prospectively evaluated.
The risk of appropriate therapies in newly diagnosed ICM was comparable to that observed in prior observational studies.
(J Am Coll Cardiol 2015;66:2607–13) © 2015 by the American College of Cardiology Foundation.S udden cardiac death (SCD) is a devastatingoutcome in patients with cardiomyopathy ofischemic (ICM) or nonischemic (NICM) etiology.
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ABBR EV I A T I ON S
AND ACRONYMS
GDMT = guideline-directed
medical therapy
ICD = implantable
cardioverter-deﬁbrillator
ICM = ischemic cardiomyopathy
LVEF = left ventricular ejection
fraction
NICM = nonischemic
cardiomyopathy
NSVT = nonsustained
ventricular tachycardia
SCD = sudden cardiac death
VF = ventricular ﬁbrillation
VT = ventricular tachycardia
WCD = wearable cardioverter-
deﬁbrillator
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2608approved by the U.S. Food and Drug Admin-
istration in 2002. There is currently a
single WCD manufacturer (ZOLL, Pittsburgh,
Pennsylvania).
Routine WCD prescription has become
widely accepted in patients with newly
diagnosed NICM during the 90-day waiting
period on GDMT before re-evaluation of left
ventricular function, despite a dearth of data
suggesting beneﬁt of WCDs in this popula-
tion. Use of the WCD in newly diagnosed ICM
has been more thoroughly investigated,
albeit not in a randomized fashion (5–7).
We report long-term experience and out-
comes with the WCD at a large academic
tertiary care center in patients with a new
diagnosis of NICM or ICM, using indepen-
dently derived data.SEE PAGE 2614METHODS
PATIENT SELECTION. This study is a retrospective
review of all consecutive patients prescribed a WCD
between June 1, 2004 andMay 30, 2015 at the hospitals
comprising the University of Pittsburgh Medical Cen-
ter to which we had access to clinical data (n ¼ 639).
Patients with an explanted ICD awaiting reimplanta-
tion (n ¼ 72), prior cardiac arrest unrelated to acute
myocardial infarction (n ¼ 10), or elevated risk of SCD
for reasons other than ICM or NICM (e.g., possible
channelopathy, n ¼ 32) were excluded from this anal-
ysis. The remaining patients had either a newly diag-
nosed NICM (n ¼ 254) or ICM (n¼ 271) with LVEF#35%
by echocardiography. All patients were identiﬁed with
ICM or NICM while hospitalized and were prescribed a
WCD upon hospital discharge at the discretion of
treating physician(s). Patient demographics and
follow-up data were obtained from the electronic
medical record. Patients were categorized as having
NICM in the absence of prior coronary revasculariza-
tion, major coronary artery stenosis $80%, deﬁnitive
biomarker evidence of prior myocardial infarction,
and imaging data suggesting prior infarction (8). The
Institutional Review Board at the University of Pitts-
burgh approved this study.
PATIENT FOLLOW-UP. All patients were prescribed
maximally tolerated GDMT, including beta-adrenergic
antagonists and inhibitors of the renin-angiotensin-
aldosterone axis. Re-evaluation of LVEF by echocar-
diography or cardiac magnetic resonance imaging was
performed after 40 days in patients with non-
revascularized acute myocardial infarction, and after90 days in patients with coronary revascularization,
new NICM diagnosis, or new ICM diagnosis without
revascularization or acute myocardial infarction.
Patients were ﬁtted with a WCD before hospital
discharge and were counseled on its operation
and the importance of wearing it. The ordering
physician prescribed tachyarrhythmia rate cutoffs,
usually with a ventricular tachycardia (VT) zone of
180 to 199 beats/min and a ventricular ﬁbrillation
(VF) zone $200 beats/min. Patient WCD shock data
were obtained from the manufacturer and electronic
medical record, and an electrophysiologist analyzed
rhythm strips to determine their appropriateness.
Patient compliance was assessed automatically by
real-time monitoring.
STATISTICAL ANALYSIS. Discrete variables are listed
as absolute numbers and percentages and were
compared using chi-square or Fisher exact tests, as
deemed appropriate. Normally distributed contin-
uous variables are listed as mean  SD and were
compared using Student t tests. Nonparametric
continuous variables are listed as medians with
interquartile ranges (IQRs), and were compared using
the Mann-Whitney U test. All p values are 2-sided,
and a p value #0.05 was considered statistically sig-
niﬁcant. All statistical analyses were performed using
SPSS version 22.0 (IBM, Armonk, New York).
RESULTS
Between June 2004 and May 2015, 525 WCDs were
prescribed for newly diagnosed NICM (n ¼ 254; 48%)
and ICM (n ¼ 271; 52%). Baseline characteristics for
each group are noted in Table 1. Notably, non-
sustained ventricular tachycardia (NSVT) was detec-
ted before WCD prescription during telemetry
monitoring in 89 (35%) NICM and 108 (40%) ICM pa-
tients (p ¼ 0.27). Use of WCDs increased during our
decade-long experience (Figure 1). Speciﬁc clinical
indications for WCDs within ICM and NICM groups
are depicted in Figures 2 and 3, respectively.
WCD UTILIZATION. The WCD was worn for a total
of 37,765 patient-days (103 patient-years), with each
patient using the WCD for a median of 61 days
(IQR: 25 to 102 days), and a daily median compliance
of 22 h (IQR: 17 to 23 h). Daily compliance was greater
in ICM patients (median 23 vs. 21 h; p ¼ 0.001),
whereas NICM patients wore the WCD for a longer
duration (median 71 vs. 53 days; p ¼ 0.004).
PATIENT OUTCOMES. During follow-up, 100 new
NICM patients (39%) had an LVEF improvement to
>35%, obviating consideration of a prophylactic
ICD. Another 6 patients did not want an ICD. Other
TABLE 1 Characteristics of Study Patients According to Cardiomyopathy Etiology
NICM (n ¼ 254) ICM (n ¼ 271) p Value
Age, yrs 57  15 65  12 <0.001
Male 176 (69) 197 (73) 0.39
Any atrial ﬁbrillation 96 (39) 79 (31) 0.06
Diabetes 45 (18) 100 (37) <0.001
Hypertension 122 (50) 177 (69) <0.001
Serum creatinine, mg/dl 1.00 (0.90-1.30) 1.04 (0.90-1.30) 0.16
Nonsustained ventricular tachycardia 89 (35) 108 (40) 0.27
Time from recent revascularization, days NA 9  8 NA
LV ejection fraction, % 23  8 26  7 <0.001
LV end-diastolic dimension, cm 6.0  1.0 5.5  0.8 <0.001
LV end-systolic dimension, cm 5.2  1.1 4.6  0.9 <0.001
QRS duration, ms 100 (90-118) 102 (90-125) 0.79
QRS morphology <0.001
Narrow (<120 ms) 194 (76) 196 (72)
Right bundle-branch block 4 (2) 21 (8)
Left bundle-branch block 49 (19) 20 (7)
Nonspeciﬁc IVCD 3 (1) 30 (11)
Paced 4 (2) 3 (1)
Beta-adrenergic antagonist 226 (89) 245 (91) 0.50
ACE-I and/or ARB 216 (85) 192 (71) <0.001
Antiarrhythmic drug 40 (16) 45 (17) 0.78
Diuretic 195 (78) 186 (70) 0.038
Digoxin 34 (13) 18 (7) 0.010
Values are mean  SD, n (%), or median (interquartile range).
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; ICM ¼ ischemic car-
diomyopathy; IVCD ¼ intraventricular conduction delay; LV ¼ left ventricular; NA ¼ not available; NICM ¼
nonischemic cardiomyopathy.
FIGURE 1 Number of WCDs Worn Each Year Since its Introduction
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Data for year 10 do not include patients from 3 of 4 UPMC hospitals because
the WCD manufacturer would not provide wear-time data on our patients.
UPMC ¼ University of Pittsburgh Medical Center; WCD ¼ wearable
cardioverter-deﬁbrillator.
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2609outcomes included lack of follow-up (n ¼ 23), heart-
lung transplantation (n ¼ 1), ventricular assist de-
vice implantation (n ¼ 2), persistent New York Heart
Association functional class IV heart failure (n ¼ 1),
and death (n ¼ 2). An additional 12 patients are
currently awaiting LVEF recovery. Ultimately, 107
(42%) patients have undergone ICD implantation for
primary prevention because of a persistently
depressed LVEF.
Among ICM patients, 88 (32%) recovered their
LVEF to >35% and did not receive a prophylactic
ICD. Another 10 elected not to pursue device im-
plantation. Other outcomes included lack of follow-
up (n ¼ 10), ventricular assist device implantation
(n ¼ 2), deferral of an ICD because of poor patient
prognosis (n ¼ 9), and death (n ¼ 9). Eighteen pa-
tients are awaiting possible LVEF improvement.
A similar percentage of ICM patients (n ¼ 125, 46%)
have been implanted with an ICD compared to NICM
patients (p ¼ 0.41).
WCD SHOCKS. No NICM patients (0 of 254; 0%)
received an appropriate shock from the WCD during
20,711 patient-days (56.7 patient-years). Among ICM
patients, 6 of 271 (2.2%) received an appropriate shock
for VF during 17,056 patient-days (46.7 patient-
years), which equates to 1 shock/2,843 patient-days
(1 shock/7.8 patient-years). Four of these patients
received a permanent ICD; 1 died from bradycardia
after successful WCD deﬁbrillation, and another died
from complications 2 days after the WCD shock
(Table 2). Another ICM patient had multiple recorded
episodes of VT associated with pre-syncope, but
deactivated the device several times before therapy
was delivered and seeking medical attention. All ICM
patients with an appropriate shock were male and
had a QRS duration >120 ms and either right bundle-
branch block or nonspeciﬁc intraventricular conduc-
tion delay. The mean time from initiating WCD use to
the ﬁrst appropriate shock was 34  11 days (median
35 days, range 17 to 45 days).
In contrast, 3 of 254 (1.2%) NICM patients received
an inappropriate shock, all of which were for artifacts
misinterpreted as ventricular tachyarrhythmia. Two
ICM patients (0.7%) received an inappropriate shock,
1 for rapidly conducted atrial ﬁbrillation and the
other for artifact.
DISCUSSION
In this study of patients with newly diagnosed car-
diomyopathy prescribed a WCD, the incidence of
appropriate shock(s) was 0.6% during a median wear
time of 61 days, for a total of 103 patient-years,
with no appropriate shocks delivered in new NICMpatients during 56.7 patient-years. Six appropriate
shocks were delivered by the WCD among newly
diagnosed ICM patients, all of whom were male and
had abnormal intraventricular conduction, although
FIGURE 2 Indications for the WCD Among Patients With ICM
New ICM without recent
revascularization
STEMI
Recent CABG or valve
NSTEMI
4%
52%
19%
25%
The 271 total ischemic cardiomyopathy patients include 141 with new ischemic
cardiomyopathy without recent revascularization, 67 with STEMI, 52 with
recent CABG or valve surgery, and 11 with NSTEMI. CABG ¼ coronary artery
bypass graft; ICM ¼ ischemic cardiomyopathy; NSTEMI ¼ non-ST-segment
elevation myocardial infarction; STEMI ¼ ST-segment elevation myocardial
infarction; WCD ¼ wearable cardioverter-deﬁbrillator.
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2610only 4 were discharged alive with an ICD (Central
Illustration). Despite these low rates of appropriate
WCD discharges, WCD prescriptions increased
signiﬁcantly during our 10-year experience.
Among newly diagnosed ICM patients, our data add
to those from post-myocardial infarction studies in
which the early risk of SCD is not insigniﬁcant (9). The
6 appropriate WCD shocks were delivered 34  11 days3 Indications for the WCD Among Patients With NICM
82%
15%
1% 0% 0% Idiopathic NICM
Tachycardia-induced
Valvular with recent
repair/replacement
Takotsubo
Peripartum
Post transplant
atients, 207 had new idiopathic cardiomyopathy, 39 had a tachycardia-
cardiomyopathy, 5 had valvular cardiomyopathy with recent surgical
r replacement, and 1 each had Takotsubo cardiomyopathy, peripartum
yopathy, and post-transplantation cardiomyopathy. NICM ¼ non-
cardiomyopathy; WCD ¼ wearable cardioverter-deﬁbrillator.after its prescription, somewhat longer than in a prior
study (5). Yet the success of WCD deﬁbrillation must
be tempered by the immediate death of 1 of the 6 pa-
tients appropriately treated by the WCD, despite re-
turn of an organized rhythm, and another patient
dying within 48 h of a WCD shock from complications.
These deaths reduce the number of WCD “saves” to 4
of 271 (1.5%) and refocus attention on the DINAMIT
(Deﬁbrillator in Acute Myocardial Infarction Trial) and
IRIS (Immediate Risk-Stratiﬁcation Improves Sur-
vival) studies, demonstrating that ICDs decrease
sudden, arrhythmic death, but do not diminish overall
mortality (10,11). It is unclear whether the capacity to
provide post-shock pacing, as occurs in ICDs, would
alter such outcomes. Even in patients with an ICD, at
least 25% of all deaths are sudden (12).
Data from previous studies investigating outcomes
in patients with NICM suggest that the impact of
deﬁbrillators on reduction of SCD in patients during
the ﬁrst 90 days on GDMT is low (2,3). Although
in DEFINITE (Deﬁbrillators in Non-Ischemic Cardio-
myopathy Treatment Evaluation), patients implanted
with an ICD early (#3 months) after NICM diagnosis
demonstrated improved survival compared to pa-
tients without an ICD, this beneﬁt was not observed
early after implantation, and patient numbers were
small (13). A recent retrospective study reported a low
incidence of appropriate ICD shocks in patients who
received an ICD before mandated waiting periods
were complete (14).
Paradoxically, on the basis of our center’s experi-
ence, it appears that newly diagnosed NICM patients
are prescribed the WCD as frequently as those with a
newly diagnosed ICM, in whom published literature
and our results indicate that the beneﬁt is not negli-
gible (6,7,15). The reason for this may be linked to
factors such as the younger age of patients diagnosed
with NICM and overestimation of the true risk of SCD
in patients with a newly diagnosed NICM. Clinically,
one of the more common reasons for prescribing a
WCD in patients with newly diagnosed NICM is
recognition of NSVT, which is often asymptomatic
and incidentally noted during telemetry monitoring.
Interestingly, despite a signiﬁcant proportion (35%)
of our NICM patient population with documented
NSVT (likely an underestimate because of the variable
intensity of monitoring), the incidence of SCD was
0%. Based on our data, there seems to be a discon-
nection between the clinician-perceived risk and the
actual risk of SCD. Visceral reactions, incomplete
knowledge of existing data, and concerns over liti-
gation may color clinicians’ decisions to prescribe a
WCD. The last concern may explain different WCD
prescribing practices in Germany versus the United
TABLE 2 Speciﬁc Characteristics and Outcomes of ICM Patients With Appropriate Wearable Cardioverter-Deﬁbrillator Shocks
Patient # Speciﬁc Indication
Prior
NSVT
Days From WCD
Start to Shock
Shock
Rhythm QRS
LVEF
(%)
ICD
Implanted Status
1 New ICM
Remote CABG 5 yrs before WCD
Yes 40 VF 152 ms
RBBB
35 No Died 2 d after WCD shock
2 New ICM
MVR 6 d after WCD
Remote CABG 22 yrs before WCD
Yes 45 VF 150 ms
RBBB
27 No Died from asystole after WCD shock
3 New ICM
STEMI with RCA stent 12 days
before WCD
Yes 31 VT 128 ms
IVCD
27 Yes Lost to follow-up after 11 months
4 New ICM
Remote CABG 16 yrs before WCD
Yes 43 VT 158 ms
RBBB
27 Yes Died 9 months after ICD
5 New ICM
Recent CABG 22 days before WCD
No 28 VF 138 ms
IVCD
22 Yes Died 71 months after ICD
6 New ICM
Remote CABG 566 days before WCD
Yes 17 VF 124 ms
IVCD
22 Yes Alive 3 months after ICD
CABG ¼ coronary artery bypass graft; ICD ¼ implantable cardioverter-deﬁbrillator; LVEF ¼ left ventricular ejection fraction; MVR ¼ mitral valve replacement; NSVT ¼ non-
sustained ventricular tachycardia; RBBB ¼ right bundle-branch block; RCA ¼ right coronary artery; STEMI ¼ ST-segment elevation myocardial infarction; VF ¼ ventricular
ﬁbrillation; VT ¼ ventricular tachycardia; WCD ¼ wearable cardioverter-deﬁbrillator; other abbreviations as in Table 1.
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2611States (16). Prescribing a WCD may foster additional
emotional trauma in newly diagnosed NICM patients;
the WCD serves as a constant reminder of their
illness, and patients often express concern over the
cumbersome nature of the WCD (17).
Industry-sponsored publications have investi-
gated WCD experience, but independent data
assessing the WCD’s utility in patients with newly
diagnosed cardiomyopathy, particularly NICM, have
been lacking. No study has validated the role of
WCDs in preventing early SCD compared to GDMT
alone. The WEARIT-I/BIROAD registry enrolled 289
patients at high risk of SCD but who were not able to
receive an ICD (17). The exact proportions of patients
within pre-speciﬁed categories of SCD risk were
not published. The risk of appropriate WCD shocks
was 2.8%, although 2 of 8 patients who received a
shock were not successfully deﬁbrillated, and 6
(2.1%) patients received an inappropriate shock.
Among WEARIT patients, 30% discontinued WCD
use because of comfort and lifestyle issues, and
in BIROAD, 11% discontinued the WCD. In the
WEARIT II registry (18), 22 (1.1%) of 2,000 patients
with ICM (40%), NICM (46%), or congenital heart
disease (13%) were shocked for ventricular tachyar-
rhythmias, and the inappropriate shock rate was
0.5%. The prospective, randomized VEST (Vest Pre-
vention of Early Sudden Death Trial) continued
enrolling post-myocardial infarction patients with
LVEF #35% until September 2015. In a published
report, using data provided by ZOLL, Chung et al.
(15) reported an overall incidence of 1.7% for
appropriate shocks in a nationwide WCD registry
that included primary prevention patients,secondary prevention patients, and patients with an
explanted ICD. There were 4 VT/VF events in 546
new NICM patients who wore the WCD for 57  59
days, corresponding to 1 appropriate shock over
7,712 patient-days. One NICM patient wearing a WCD
died from VT/VF, but it is not clear whether this
patient was shocked. The authors reported 12 pa-
tients shocked appropriately among 584 recent
myocardial infarction or coronary artery bypass
graft patients using the WCD for 47  41 days, cor-
responding to 1 appropriate shock over 2,302
patient-days. Three ICM patients died from VT/VF
while wearing the WCD, but it is unclear whether
shocks were delivered. Another study reported
133 appropriate patient shocks among 8,678 post-
myocardial infarction patients prescribed a WCD
for 69  61 days, yielding 1 shock per 4,502 patient-
days (5).
Interestingly, in our study, all 3 shocks in pa-
tients with NICM and 1 of 2 shocks in ICM patients
were delivered for artifacts misinterpreted as ven-
tricular tachyarrhythmias. Although the WCD allows
the patient to suppress a shock if he or she is
conscious and, therefore, presumably not hemody-
namically compromised, it is not clear why this did
not occur in the patients with inappropriate shocks.
One possibility is poor understanding of device
function by the patient or patient reluctance to
abort the shock out of fear of interfering with
device function.
The cost associated with WCD use is substantial;
the estimated rental cost is approximately $3,300/
month (manufacturer data). During the past 10 years,
approximately $2.2 million were spent on providing
CENTRAL ILLUSTRATION Wearable Cardioverter-Deﬁbrillators for New Cardiomyopathy: Summary of Study Outcomes in
10-Year Follow-Up
Idiopathic
0      50   100   150   200
1 Died from 
Asystole Immediately
1 Died <48 Hours
Later
4 Survived and Received ICD                               0 Lives Saved
*All 6 Patients
  •Male
  •QRS Interval >120 ms
  •RBBB or Non-LBBB
   IVCD
0          50      100
        525 Patients with Newly 
     Diagnosed Cardiomyopathy 
n = 1
n = 1
n = 1
2 Inappropriate Shocks       6 Appropriate Shocks* 0 Appropriate Shocks        3 Inappropriate Shocks
        271
   Ischemic 
46.7 Patient-Years
         254
 Nonischemic
         
56.7 Patient-Years
21 Hours/Day
71 Days
23 Hours/Day
53 Days
NSTEMI
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Tachycardia-Induced
Takotsubo
Peripartum
Transplant
Valvular with recent
 repair/replacement
Recent CABG or
CABG/valve
New ICM, no recent
revascularization
Singh, M. et al. J Am Coll Cardiol. 2015; 66(23):2607–13.
In this decade-long evaluation, decade-long study outcomes are presented in patients with newly diagnosed cardiomyopathy prescribed a wearable
cardioverter-deﬁbrillator. CABG ¼ coronary artery bypass graft; ICD ¼ implantable cardioverter-deﬁbrillator; ICM ¼ ischemic cardiomyopathy; IVCD ¼
intraventricular conduction delay; LBBB ¼ left bundle-branch block; NSTEMI ¼ nonST-segment elevation myocardial infarction; RBBB ¼ right bundle-
branch block; STEMI ¼ ST-segment elevation myocardial infarction.
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2612coverage for the WCD in patients with NICM at our
center. Better predictors of early SCD in patients
with newly diagnosed NICM need to be identiﬁed,
instead of prescribing a WCD for all such patients, as
is quickly becoming the standard of care. Larger,
randomized trials should be pursued to address this
issue. The increasing rates of WCD use over time
(Figure 1) suggest that the WCD may be preventing
inappropriate ICD implantations, as one-third of pa-
tients in our study experienced LVEF improvement
and were therefore spared an ICD. In this manner, the
beneﬁt of WCDs cannot be based wholly on the inci-
dence of appropriate shocks. Whether the cost sav-
ings of reduced inappropriate ICD implantations
exceeds the cost of prescribing WCDs also requires
additional study.STUDY LIMITATIONS. To our knowledge, this is the
ﬁrst study speciﬁcally investigating outcomes using
the WCD in patients with newly diagnosed ICM and
NICM that does not rely wholly on the manufacturer’s
data. Prior WCD studies have focused on patients with
ICM and have relied on the manufacturer’s database
for data extraction. Although the present study is
relatively small, independent investigators abstracted
the data, and we have investigator-proven WCD in-
dications and heart failure etiologies. The present
study encompasses a heterogeneous group of patients
and spans the use of WCDs over a decade. It is limited,
however, because of its design as a retrospective chart
review, and we cannot ascertain whether WCD use
improves mortality compared to nonuse. We also
cannot determine whether there were differences
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The risk of
sustained ventricular tachyarrhythmias requiring therapy from
a WCD is minimal in patients with newly diagnosed NICM and
greater, but still small, in patients with newly diagnosed ICM.
TRANSLATIONAL OUTLOOK: Further studies are needed
to identify optimal candidates for WCDs and improve the
performance characteristics of these devices.
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2613in new NICM or ICM patients prescribed a WCD
compared to those not referred for a WCD at our
institution. Additionally, some patients were lost to
follow-up. Finally, although there were no appro-
priate shocks in newly diagnosed NICM patients
in the present study, this does not imply that the
risk of ventricular arrhythmias in this population is
zero.
CONCLUSIONS
The practice of prescribing a WCD for all patients with
newly diagnosed NICM is of limited utility, even in
the presence of nonsustained ventricular arrhyth-
mias. Further trials should be undertaken before this
practice becomes the standard of care. In contrast,
patients with newly diagnosed ICM have a small but
signiﬁcant risk of ventricular tachyarrhythmias, and
the WCD may mitigate this risk.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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